O

Oncovista Innovative Therapies Inc
OTC:OVIT

Watchlist Manager
Oncovista Innovative Therapies Inc
OTC:OVIT
Watchlist
Price: 0.0001 USD -50% Market Closed
Market Cap: 2.4k USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Oncovista Innovative Therapies Inc
OTC:OVIT
2.4k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Oncovista Innovative Therapies Inc
Glance View

Market Cap
2.4k USD
Industry
Biotechnology

OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company is headquartered in San Antonio, Texas. The company went IPO on 2006-01-23. The firm is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The firm's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The firm's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The firm's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.

OVIT Intrinsic Value
Not Available
O
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top